Oxycodone And Acetaminophen side effects: what 23,161 FDA adverse event reports show
Drug class
Not stated in label
Label matched
Oxycodone (Oxycodone Hydrochloride)
Who reports
23,161 reports · 82% serious · 2,940 with death outcome · 55% female
Used for
Oxycodone hydrochloride (HCl) tablets are indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Limitations of Use Because of the risks of addiction, abuse, misuse, overdo.
What it is
Oxycodone HCl tablets, USP contains oxycodone, an opioid agonist.
Boxed warning
SERIOUS AND LIFE-THREATENING RISKS FROM USE OF OXYCODONE HCl Addiction, Abuse, and Misuse Because the use of oxycodone HCl exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which c.
Causality screen of the 40 strongest signals
What the badges mean
- Labeled — boxed warning The term (or its clinical synonym) appears in the FDA boxed warning: causality is regulator-recognised and considered serious.
- Labeled adverse reaction The exact term appears in the label's warnings or adverse-reactions sections: a known, expected effect. The FAERS signal confirms the label rather than discovering anything.
- Labeled (related wording) The label describes this effect under different wording (e.g. 'neutropenia' for 'neutrophil count decreased'). Treated as known.
- Reporting / coding artifact An administrative, monitoring or exposure term (product issue, off-label use, 'test normal', overdose...). Not a biological reaction; a high PRR here reflects how reports are coded.
- Lab value / disease marker A laboratory result, investigation or disease-activity marker (antibody positive, CRP abnormal, swollen joint count) not described in the label. These usually mirror the monitored disease or testing protocol rather than a drug effect; not screened further.
- Not in label — unassessed Not found in the label text, not an artifact pattern. This is a genuine candidate for a formal causality assessment (Bradford Hill / WHO-UMC); it has NOT had one here.
Strongest disproportionality signals
Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only (and, for the 300 most-reported drugs, adjusted for age band), and flags pairs whose reports are unusually skewed by sex or come mostly from consumers. Each row also shows the PRR against the other drugs of the same FDA class, which removes most confounding by the condition being treated, and a calibrated p-value: on validation, known non-causes average an ROR of about 2, so significance is judged against that empirical null (✓ = p < 0.05 after calibration). 1,098 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.
| Reaction | Reports | PRR 95% CI · ROR · χ²/p | EBGM EB05 · IC025 | Label screen | Serious-only & strata | Trial cross-check |
|---|---|---|---|---|---|---|
| Vision abnormal neonatal | 71 | 182.5 141.5–235.6ROR 183.1 · calibrated p 2e-9 ✓ | 145.8 EB05 119.5 · IC025 +5.8 3/3 methods agree | Not in label — unassessed | serious n=71 · 100% consumer | no trial arm names this drug |
| Grip strength | 38 | 177.5 125.3–251.3ROR 177.8 · calibrated p 3e-9 ✓ | 138.1 EB05 105.0 · IC025 +5.1 3/3 methods agree | Not in label — unassessed | serious n=38 · ♀ 100% (drug 55%) · 100% clinician | no trial arm names this drug |
| Dependence | 8,736 | 169.1 165.9–172.3ROR 270.8 · calibrated p 2e-11 ✓ | 142.3 EB05 139.8 · IC025 +7.1 3/3 methods agree | Labeled adverse reaction exact term | serious PRR 100.6 · 100% consumer | no trial arm names this drug |
| Swollen joint count | 29 | 120.9 82.0–178.1ROR 121.0 · calibrated p 8e-8 ✓ | 99.8 EB05 72.8 · IC025 +4.6 3/3 methods agree | Not in label — unassessed | serious n=29 · ♀ 100% (drug 55%) · 100% clinician | no trial arm names this drug |
| Neonatal hypoacusis | 26 | 112.6 74.9–169.3ROR 112.7 · calibrated p 1e-7 ✓ | 93.4 EB05 67.0 · IC025 +4.5 3/3 methods agree | Not in label — unassessed | serious n=26 · 100% consumer | no trial arm names this drug |
| Deep vein thrombosis postoperative | 184 | 93.7 80.5–109.0ROR 94.4 · calibrated p 2e-7 ✓ | 84.2 EB05 74.4 · IC025 +5.9 3/3 methods agree | Not in label — unassessed | serious n=184 · ♀ 100% (drug 55%) · 96% clinician | no trial arm names this drug |
| Lupus vulgaris | 101 | 83.9 68.4–102.8ROR 84.3 · calibrated p 5e-7 ✓ | 75.7 EB05 64.1 · IC025 +5.5 3/3 methods agree | Not in label — unassessed | serious n=101 · ♀ 100% (drug 55%) · 100% clinician | no trial arm names this drug |
| Sleep disorder due to general medical condition, insomnia type | 522 | 79.8 73.1–87.2ROR 81.7 · calibrated p 5e-7 ✓ | 73.2 EB05 68.1 · IC025 +6.0 3/3 methods agree | Labeled (related wording) related wording | serious n=521 · ♀ 100% (drug 55%) · 93% clinician | no trial arm names this drug |
| Subcutaneous drug absorption impaired | 44 | 79.5 58.4–108.1ROR 79.6 · calibrated p 1e-6 ✓ | 70.9 EB05 55.0 · IC025 +4.8 3/3 methods agree | Labeled (related wording) related wording | serious n=44 · ♀ 100% (drug 55%) · 100% clinician | no trial arm names this drug |
| Muscle injury | 622 | 74.2 68.4–80.4ROR 76.2 · calibrated p 8e-7 ✓ | 68.4 EB05 64.0 · IC025 +5.9 3/3 methods agree | Labeled (related wording) related wording | serious PRR 52.0 · ♀ 100% (drug 55%) · 94% clinician | no trial arm names this drug |
| X-ray abnormal | 132 | 72.2 60.5–86.2ROR 72.7 · calibrated p 1e-6 ✓ | 66.3 EB05 57.3 · IC025 +5.5 3/3 methods agree | Lab value / disease marker | serious n=132 · ♀ 100% (drug 55%) · 95% clinician | no trial arm names this drug |
| Duodenal ulcer perforation | 539 | 71.7 65.7–78.2ROR 73.4 · calibrated p 1e-6 ✓ | 66.3 EB05 61.7 · IC025 +5.8 3/3 methods agree | Not in label — unassessed | serious PRR 46.5 · ♀ 100% (drug 55%) · 93% clinician | no trial arm names this drug |
| Anti-cyclic citrullinated peptide antibody | 49 | 71.7 53.6–95.8ROR 71.8 · calibrated p 2e-6 ✓ | 64.8 EB05 51.0 · IC025 +4.8 3/3 methods agree | Lab value / disease marker | serious n=49 · ♀ 100% (drug 55%) · 100% clinician | no trial arm names this drug |
| Anti-cyclic citrullinated peptide antibody positive | 519 | 71.3 65.2–77.9ROR 72.9 · calibrated p 1e-6 ✓ | 65.9 EB05 61.3 · IC025 +5.8 3/3 methods agree | Lab value / disease marker | serious PRR 46.5 · ♀ 100% (drug 55%) · 93% clinician | no trial arm names this drug |
| Adjustment disorder with depressed mood | 145 | 70.1 59.2–83.0ROR 70.5 · calibrated p 2e-6 ✓ | 64.5 EB05 56.2 · IC025 +5.5 3/3 methods agree | Not in label — unassessed | serious n=145 · ♀ 100% (drug 55%) · 96% clinician | no trial arm names this drug |
| C-reactive protein | 63 | 67.5 52.2–87.1ROR 67.7 · calibrated p 3e-6 ✓ | 61.7 EB05 49.9 · IC025 +5.0 3/3 methods agree | Lab value / disease marker | serious n=63 · ♀ 100% (drug 55%) · 100% clinician | no trial arm names this drug |
| Learning disability | 357 | 64.1 57.6–71.3ROR 65.1 · calibrated p 3e-6 ✓ | 59.7 EB05 54.7 · IC025 +5.6 3/3 methods agree | Not in label — unassessed | serious n=357 · 100% consumer | no trial arm names this drug |
| Swollen joint count increased | 201 | 62.3 54.0–71.8ROR 62.8 · calibrated p 3e-6 ✓ | 58.0 EB05 51.6 · IC025 +5.4 3/3 methods agree | Lab value / disease marker | serious n=201 · ♀ 100% (drug 55%) · 95% clinician | no trial arm names this drug |
| Dislocation of vertebra | 138 | 59.8 50.4–71.0ROR 60.2 · calibrated p 5e-6 ✓ | 55.7 EB05 48.3 · IC025 +5.3 3/3 methods agree | Not in label — unassessed | serious n=138 · ♀ 100% (drug 55%) · 94% clinician | no trial arm names this drug |
| Folliculitis | 634 | 59.2 54.6–64.0ROR 60.8 · calibrated p 4e-6 ✓ | 55.5 EB05 51.9 · IC025 +5.6 3/3 methods agree | Not in label — unassessed | serious PRR 45.8 · ♀ 100% (drug 55%) · 93% clinician | no trial arm names this drug |
| Porphyria acute | 77 | 53.4 42.5–67.2ROR 53.6 · calibrated p 1e-5 ✓ | 49.9 EB05 41.2 · IC025 +4.9 3/3 methods agree | Not in label — unassessed | serious n=77 · ♀ 100% (drug 55%) · 92% clinician | no trial arm names this drug |
| Helicobacter infection | 554 | 52.0 47.8–56.6ROR 53.2 · calibrated p 9e-6 ✓ | 49.1 EB05 45.8 · IC025 +5.4 3/3 methods agree | Not in label — unassessed | serious PRR 36.4 · ♀ 100% (drug 55%) · 94% clinician | no trial arm names this drug |
| Facet joint syndrome | 166 | 50.3 43.0–58.7ROR 50.6 · calibrated p 1e-5 ✓ | 47.4 EB05 41.6 · IC025 +5.1 3/3 methods agree | Not in label — unassessed | serious n=166 · ♀ 100% (drug 55%) · 91% clinician | no trial arm names this drug |
| Ill-defined disorder | 3,100 | 48.6 47.0–50.3ROR 56.0 · calibrated p 7e-6 ✓ | 46.1 EB05 44.8 · IC025 +5.5 3/3 methods agree | Not in label — unassessed | serious PRR 48.7 · 85% consumer | no trial arm names this drug |
| Rheumatic fever | 218 | 47.5 41.5–54.4ROR 47.9 · calibrated p 2e-5 ✓ | 45.0 EB05 40.2 · IC025 +5.1 3/3 methods agree | Not in label — unassessed | serious n=218 · ♀ 100% (drug 55%) · 94% clinician | no trial arm names this drug |
| Retinitis | 77 | 43.7 34.8–54.9ROR 43.9 · calibrated p 4e-5 ✓ | 41.3 EB05 34.2 · IC025 +4.7 3/3 methods agree | Not in label — unassessed | serious n=77 · ♀ 100% (drug 55%) · 100% clinician | no trial arm names this drug |
| Pemphigus | 560 | 42.7 39.2–46.4ROR 43.7 · calibrated p 3e-5 ✓ | 40.7 EB05 38.0 · IC025 +5.2 3/3 methods agree | Not in label — unassessed | serious PRR 28.7 · ♀ 100% (drug 55%) · 94% clinician | no trial arm names this drug |
| Developmental delay | 391 | 40.6 36.7–44.9ROR 41.3 · calibrated p 4e-5 ✓ | 38.8 EB05 35.7 · IC025 +5.0 3/3 methods agree | Not in label — unassessed | serious PRR 27.7 · 100% consumer | no trial arm names this drug |
| Hand deformity | 561 | 40.5 37.3–44.1ROR 41.5 · calibrated p 4e-5 ✓ | 38.8 EB05 36.1 · IC025 +5.1 3/3 methods agree | Not in label — unassessed | serious PRR 29.6 · ♀ 100% (drug 55%) · 93% clinician | no trial arm names this drug |
| Drug withdrawal syndrome neonatal | 616 | 38.8 35.9–42.1ROR 39.9 · calibrated p 5e-5 ✓ | 37.2 EB05 34.8 · IC025 +5.0 3/3 methods agree | Labeled adverse reaction exact term | serious PRR 26.2 · 100% consumer | no trial arm names this drug |
| Rheumatoid factor positive | 222 | 36.2 31.7–41.4ROR 36.5 · calibrated p 9e-5 ✓ | 34.7 EB05 31.1 · IC025 +4.8 3/3 methods agree | Lab value / disease marker | serious n=222 · ♀ 100% (drug 55%) · 95% clinician | no trial arm names this drug |
| Peripheral venous disease | 152 | 35.8 30.4–42.1ROR 36.0 · calibrated p 1e-4 ✓ | 34.3 EB05 30.0 · IC025 +4.7 3/3 methods agree | Labeled (related wording) related wording | serious n=152 · ♀ 100% (drug 55%) · 93% clinician | no trial arm names this drug |
| Product used for unknown indication | 47 | 35.4 26.5–47.4ROR 35.5 · calibrated p 1e-4 ✓ | 33.7 EB05 26.3 · IC025 +4.2 3/3 methods agree | Reporting / coding artifact | serious n=47 · ♀ 0% (drug 55%) | no trial arm names this drug |
| Presbyacusis | 11 | 33.2 18.2–60.5ROR 33.2 · calibrated p 5e-4 ✓ | 30.4 EB05 18.1 · IC025 +2.7 3/3 methods agree | Not in label — unassessed | serious n=11 | no trial arm names this drug |
| Pericarditis | 555 | 31.2 28.7–33.9ROR 31.9 · calibrated p 2e-4 ✓ | 30.1 EB05 28.1 · IC025 +4.7 3/3 methods agree | Not in label — unassessed | serious PRR 21.3 · ♀ 100% (drug 55%) · 93% clinician | no trial arm names this drug |
| Substance use disorder | 94 | 28.5 23.2–35.0ROR 28.6 · calibrated p 4e-4 ✓ | 27.5 EB05 23.2 · IC025 +4.3 3/3 methods agree | Labeled adverse reaction exact term | serious n=93 · 100% consumer | no trial arm names this drug |
| Irritable bowel syndrome | 650 | 28.4 26.3–30.6ROR 29.2 · calibrated p 3e-4 ✓ | 27.5 EB05 25.8 · IC025 +4.6 3/3 methods agree | Not in label — unassessed | serious PRR 24.4 · ♀ 98% (drug 55%) · 91% clinician | no trial arm names this drug |
| Synovitis | 536 | 27.7 25.4–30.1ROR 28.3 · calibrated p 4e-4 ✓ | 26.9 EB05 25.0 · IC025 +4.6 3/3 methods agree | Not in label — unassessed | serious PRR 19.7 · ♀ 100% (drug 55%) · 94% clinician | no trial arm names this drug |
| Withdrawal syndrome | 1,148 | 25.3 23.9–26.8ROR 26.5 · calibrated p 5e-4 ✓ | 24.6 EB05 23.4 · IC025 +4.5 3/3 methods agree | Labeled — boxed warning exact term | serious PRR 24.3 · 98% consumer | no trial arm names this drug |
| Glossodynia (burning tongue/mouth pain) | 565 | 23.4 21.6–25.5ROR 24.0 · calibrated p 8e-4 ✓ | 22.9 EB05 21.3 · IC025 +4.3 3/3 methods agree | Labeled (related wording) related wording | serious PRR 22.9 · ♀ 99% (drug 55%) · 93% clinician | no trial arm names this drug |
Trial evidence (ClinicalTrials.gov)
Most frequently reported reactions
By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.
| Reaction | Reports | PRR 95% CI · ROR · χ²/p | EBGM EB05 · IC025 | Label screen | Serious-only & strata | Trial cross-check |
|---|---|---|---|---|---|---|
| Dependence | 8,736 | 169.1 165.9–172.3ROR 270.8 · calibrated p 2e-11 ✓ | 142.3 EB05 139.8 · IC025 +7.1 3/3 methods agree | Labeled adverse reaction exact term | serious PRR 100.6 · 100% consumer | no trial arm names this drug |
| Overdose | 4,114 | 17.5 17.0–18.0ROR 21.1 · calibrated p 0.002 ✓ | 17.2 EB05 16.8 · IC025 +4.0 3/3 methods agree | Reporting / coding artifact | serious PRR 15.2 · 97% consumer | no trial arm names this drug |
| Ill-defined disorder | 3,100 | 48.6 47.0–50.3ROR 56.0 · calibrated p 7e-6 ✓ | 46.1 EB05 44.8 · IC025 +5.5 3/3 methods agree | Not in label — unassessed | serious PRR 48.7 · 85% consumer | no trial arm names this drug |
| Drug ineffective (drug did not work) | 1,914 | 1.3 1.3–1.4ROR 1.3 · calibrated p 0.538 | 1.3 EB05 1.3 · IC025 +0.3 | Reporting / coding artifact | serious PRR 1.7 | no trial arm names this drug |
| Pain | 1,800 | 2.7 2.5–2.8ROR 2.8 · calibrated p 0.698 | 2.6 EB05 2.5 · IC025 +1.3 3/3 methods agree | Likely indication confounding term in indications; also in warnings | serious PRR 2.5 · ♀ 76% (drug 55%) | no trial arm names this drug |
| Death | 1,668 | 1.8 1.7–1.8ROR 1.8 · calibrated p 0.837 | 1.8 EB05 1.7 · IC025 +0.7 | Outcome field, not a reaction boxed warning mentions mortality | serious PRR 1.2 · 83% consumer | no trial arm names this drug |
| Fatigue (tiredness) | 1,622 | 1.9 1.8–2.0ROR 2.0 · calibrated p 0.921 | 1.9 EB05 1.8 · IC025 +0.8 | Labeled adverse reaction exact term | serious PRR 2.0 · ♀ 80% (drug 55%) | no trial arm names this drug |
| Nausea | 1,439 | 1.7 1.6–1.7ROR 1.7 · calibrated p 0.766 | 1.7 EB05 1.6 · IC025 +0.6 | Labeled adverse reaction exact term | serious PRR 1.6 | no trial arm names this drug |
| Dyspnoea (shortness of breath) | 1,171 | 1.9 1.8–2.0ROR 1.9 · calibrated p 0.901 | 1.9 EB05 1.8 · IC025 +0.8 | Labeled adverse reaction exact term | serious PRR 1.6 · ♀ 82% (drug 55%) | no trial arm names this drug |
| Withdrawal syndrome | 1,148 | 25.3 23.9–26.8ROR 26.5 · calibrated p 5e-4 ✓ | 24.6 EB05 23.4 · IC025 +4.5 3/3 methods agree | Labeled — boxed warning exact term | serious PRR 24.3 · 98% consumer | no trial arm names this drug |
| Drug dependence | 1,132 | 6.3 6.0–6.7ROR 6.6 · calibrated p 0.116 | 6.3 EB05 6.0 · IC025 +2.6 3/3 methods agree | Reporting / coding artifact | serious PRR 4.5 · 95% consumer | no trial arm names this drug |
| Arthralgia (joint pain) | 1,097 | 2.4 2.3–2.5ROR 2.5 · calibrated p 0.826 | 2.4 EB05 2.3 · IC025 +1.2 3/3 methods agree | Labeled adverse reaction exact term | serious PRR 2.7 · ♀ 86% (drug 55%) | no trial arm names this drug |
| Off label use (used outside approved label) | 1,063 | 1.1 1.0–1.2ROR 1.1 · calibrated p 0.382 | 1.1 EB05 1.1 · IC025 +0.0 | Reporting / coding artifact | serious PRR 1.3 | no trial arm names this drug |
| Headache | 1,048 | 1.5 1.4–1.6ROR 1.5 · calibrated p 0.668 | 1.5 EB05 1.4 · IC025 +0.5 | Labeled adverse reaction exact term | serious PRR 1.6 · ♀ 83% (drug 55%) | no trial arm names this drug |
| Anxiety | 1,048 | 3.3 3.1–3.5ROR 3.4 · calibrated p 0.499 | 3.3 EB05 3.2 · IC025 +1.6 3/3 methods agree | Labeled adverse reaction exact term | serious PRR 3.1 | no trial arm names this drug |
Unlabeled candidate signals
These flagged terms were not found in the FDA label text and do not match an artifact pattern. They are the pairs that would merit a structured assessment (temporality, dose-response, biological plausibility, consistency across databases, trial or cohort evidence). The screen has not done that; string-matching misses label wording, and a strong PRR can still be stimulated reporting, co-medication, or the disease itself.
- Vision abnormal neonatal — n=71, PRR 182.5
- Grip strength — n=38, PRR 177.5
- Swollen joint count — n=29, PRR 120.9
- Neonatal hypoacusis — n=26, PRR 112.6
- Deep vein thrombosis postoperative — n=184, PRR 93.7
- Lupus vulgaris — n=101, PRR 83.9
- Duodenal ulcer perforation — n=539, PRR 71.7
- Adjustment disorder with depressed mood — n=145, PRR 70.1
- Learning disability — n=357, PRR 64.1
- Dislocation of vertebra — n=138, PRR 59.8
✓ A hand-written Bradford Hill causality assessment exists for this drug: Oxycodone ↔ Drug dependence / withdrawal syndrome.
Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.
Common questions
What are the most reported side effects of Oxycodone And Acetaminophen?
In FDA FAERS, the most frequently co-reported reaction terms for Oxycodone And Acetaminophen are dependence, ill-defined disorder, pain, fatigue, nausea, dyspnoea. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.
Does Oxycodone And Acetaminophen have an FDA boxed warning?
Yes. The current FDA label carries a boxed warning: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF OXYCODONE HCl Addiction, Abuse, and Misuse Because the use of oxycodone HCl exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which c.
Do FAERS signals prove that Oxycodone And Acetaminophen causes these side effects?
No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.
Sources & methods
- FDA label via openFDA (set ID 6b6db42b-9821-4aa6-8566-297037d84079, effective 20260723; matched on
openfda.generic_name.exact:"OXYCODONE") - Bayesian shrinkage measures computed offline over all 1,317,300 cached pairs: BCPNN information component (IC, with Norén closed-form IC025) and MGPS empirical-Bayes geometric mean (EBGM, EB05) with a two-component gamma prior fitted by maximum marginal likelihood (α₁=0.57, β₁=0.02, α₂=1.42, β₂=0.70, w=0.17); unstratified
- FAERS pair statistics from the OpenPV build of 2026-09-14 (openFDA
count=aggregation, fieldpatient.drug.openfda.generic_name.exact, 1,138 reaction terms, min 3 co-reports); PRR/ROR with 95% CI, chi-square with Yates correction - Serious-only and stratified counts (serious:1, patient.patientsex, primarysource.qualification) from openFDA count queries; serious-only PRR uses the drug serious report total and the term global serious total (N_serious=11,882,979); strata shown only when n ≥ 20
- Seriousness and sex counts from openFDA
count=serious,patient.patientsex,seriousnessdeath - ClinicalTrials.gov API v2 (query
OXYCODONE, results-bearing studies sorted by enrollment)
Page generated 2026-10-14. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.